April 23, 2014.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) is attending the 2014 ASCRS (American Society of Cataract and Refractive Surgery) • ASOA (American Society of Ophthalmic Administrators) Symposium & Congress, taking place from April 25 to 29, 2014 in Boston, MA, United States. Nicox can be found at booth number 1201.
Several members of Nicox’s US leadership team will be present, including Jerry St Peter, Executive Vice President & General Manager, Mark Puwal, Sr. Director and Head, National Sales, Mark Jasek, Ph.D, Sr. Director and Head, Medical and Scientific Affairs and Jason Menzo, Sr. Director and Head, Marketing and Operations.
The Nicox Inc. team is excited to present Sjö™, an advanced diagnostic panel for the early detection of Sjögren’s Syndrome which was launched by Nicox in targeted US markets in November 2013. The national expansion and roll-out for Sjö™ is planned in the coming months. Additionally, the team will be presenting RetnaGene™ AMD, which is scheduled to be launched by mid-2014. RetnaGene™ AMD is a laboratorydeveloped test for the evaluation of a patient’s risk of early or intermediate age-related macular degeneration (AMD) progressing to the advanced stage of the disease, called wet AMD, within 2, 5 and 10 years. Nicox Inc. also markets AdenoPlus®, a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis, since in October 2012.
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company’s commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox’s key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox’s proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.
Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.